TRANSGENE Announces its Invesment in ElsaLys Biotech, a New Antibody Company Created by Former Executives
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene SA (Euronext Paris: TNG)(Paris:TNG), a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and chronic infectious diseases, today announced its participation to the first private equity round of Elsalys Biotech, a newly created therapeutic monoclonal antibody player.
Help employers find you! Check out all the jobs and post your resume.
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene SA (Euronext Paris: TNG)(Paris:TNG), a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and chronic infectious diseases, today announced its participation to the first private equity round of Elsalys Biotech, a newly created therapeutic monoclonal antibody player.
Help employers find you! Check out all the jobs and post your resume.